Epidemiology of urinary bladder cancer: from tumor de

World Journal of Urology 25, 285-295 DOI: 10.1007/s00345-007-0168-5

Citation Report

#	Article	IF	CITATIONS
3	A compendium of familial relative risks of cancer among first degree relatives: A populationâ€based study. International Journal of Cancer, 2008, 123, 1664-1673.	2.3	11
4	The origins of bladder cancer. Laboratory Investigation, 2008, 88, 686-693.	1.7	52
5	XRCC1 Genetic Polymorphisms and Bladder Cancer Susceptibility: A Meta-analysis. Urology, 2008, 72, 869-872.	0.5	39
6	Epidemiology, Staging, Grading, and Risk Stratification of Bladder Cancer. European Urology Supplements, 2008, 7, 618-626.	0.1	85
7	Allelic Imbalance Analysis Using a Single-Nucleotide Polymorphism Microarray for the Detection of Bladder Cancer Recurrence. Clinical Cancer Research, 2008, 14, 8198-8204.	3.2	7
8	Prevention of bladder cancer recurrence by retinoic acid-ketoconazole: A promising strategy?. Cancer Biology and Therapy, 2008, 7, 101-102.	1.5	5
9	Survival in Bladder and Renal Cell Cancers Is Familial. Journal of the American Society of Nephrology: JASN, 2008, 19, 985-991.	3.0	13
10	Apaziquone for non-muscle invasive bladder cancer: a critical review. Expert Opinion on Investigational Drugs, 2008, 17, 1085-1096.	1.9	15
11	Drugs for treating urinary schistosomiasis. , 2008, , CD000053.		46
13	A Six-Nucleotide Insertion-Deletion Polymorphism in the <i>CASP8</i> Promoter Associated with Risk and Progression of Bladder Cancer. Clinical Cancer Research, 2009, 15, 2567-2572.	3.2	36
14	Bladder cancer in cancer patients: population-based estimates from a large Swedish study. British Journal of Cancer, 2009, 101, 1091-1099.	2.9	32
15	Population-specific GSTM1 copy number variation. Human Molecular Genetics, 2009, 18, 366-372.	1.4	34
16	Strategies to improve drug delivery in bladder cancer therapy. Expert Opinion on Drug Delivery, 2009, 6, 727-744.	2.4	19
17	MDCT Urography: Exploring a New Paradigm for Imaging of Bladder Cancer. American Journal of Roentgenology, 2009, 192, 1501-1508.	1.0	39
18	Tobacco use and bladder cancer patterns in three western European countries. Journal of Public Health, 2009, 31, 335-344.	1.0	9
19	Genetic variants in the death receptor 4 gene contribute to susceptibility to bladder cancer. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2009, 661, 85-92.	0.4	19
20	Recurrence and Progression of Disease in Non–Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy. European Urology, 2009, 56, 430-442.	0.9	584
21	Sexâ€specific familial risks of urinary bladder cancer and associated neoplasms in Sweden. International Journal of Cancer, 2009, 124, 2166-2171.	2.3	16

	CITATION	Report	
#	Article	IF	CITATIONS
22	Consumption of vegetables and fruit and the risk of bladder cancer in the European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer, 2009, 125, 2643-2651.	2.3	42
23	No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in patients with bladder cancer. International Journal of Cancer, 2009, 125, 2205-2208.	2.3	20
24	Urothelial overexpression of insulinâ€like growth factorâ€1 increases susceptibility to <i>p</i> â€cresidineâ€induced bladder carcinogenesis in transgenic mice. Molecular Carcinogenesis, 2009, 48, 671-677.	1.3	18
25	Bladder cancer SNP panel predicts susceptibility and survival. Human Genetics, 2009, 125, 527-539.	1.8	85
26	Trace metals and over-expression of metallothioneins in bladder tumoral lesions: a case-control study. BMC Veterinary Research, 2009, 5, 24.	0.7	13
27	Trace metals and over-expression of metallothioneins in bladder tumoral lesions: a case-control study. BMC Veterinary Research, 2009, 5, 40.	0.7	2
28	Incidence analyses of bladder cancer in the Nile delta region of Egypt. Cancer Epidemiology, 2009, 33, 176-181.	0.8	62
29	Differences in Tumor Characteristics and Prognosis in Newly Diagnosed Ta, T1 Urothelial Carcinoma of Bladder According to Patient Age. Urology, 2009, 73, 828-832.e1.	0.5	21
30	Recurrence, Progression, and Follow-Up in Non–Muscle-Invasive Bladder Cancer. European Urology Supplements, 2009, 8, 556-562.	0.1	55
31	Current Trends in the Management of Bladder Cancer. Journal of Wound, Ostomy and Continence Nursing, 2009, 36, 413-421.	0.6	6
32	A wake up call for urinary schistosomiasis: reconciling research effort with public health importance. Parasitology, 2009, 136, 1593-1610.	0.7	123
33	Clinical characteristics of bladder urothelial tumors in female patients. Menopause, 2010, 17, 421-425.	0.8	0
34	Overexpression of BDNF and TrkB in human bladder cancer specimens. Oncology Reports, 2010, 24, 1265-70.	1.2	65
35	Bladder Cancer: A Review of Non-Muscle Invasive Disease. Cancer Control, 2010, 17, 256-268.	0.7	75
36	Diagnostic value of fibronectin and mutant p53 in the urine of patients with bladder cancer: impact on clinicopathological features and disease recurrence. Medical Oncology, 2010, 27, 1286-1294.	1.2	20
37	A meta-analysis of alcohol intake and risk of bladder cancer. Cancer Causes and Control, 2010, 21, 1843-1850.	0.8	21
38	Overexpression of Securin in Human Transitional Cell Carcinoma Specimens. Tzu Chi Medical Journal, 2010, 22, 171-176.	0.4	3
39	Downâ€regulation of type I interferon receptor sensitizes bladder cancer cells to vesicular stomatitis virusâ€induced cell death. International Journal of Cancer, 2010, 127, 830-838.	2.3	43

#	Article	IF	CITATIONS
40	Combretastatin Aâ€4 inhibits cell growth and metastasis in bladder cancer cells and retards tumour growth in a murine orthotopic bladder tumour model. British Journal of Pharmacology, 2010, 160, 2008-2027.	2.7	53
41	Amount of tobacco consumption is associated with superficial bladder cancer progression. Einstein (Sao Paulo, Brazil), 2010, 8, 473-476.	0.3	5
42	Selenium and Bladder Cancer Risk: a Meta-analysis. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2407-2415.	1.1	96
43	Dairy Intake and the Risk of Bladder Cancer in the Netherlands Cohort Study on Diet and Cancer. American Journal of Epidemiology, 2010, 171, 436-446.	1.6	39
44	Cyclin D1 G870A Polymorphism Is Associated with Risk and Clinicopathologic Characteristics of Bladder Cancer. DNA and Cell Biology, 2010, 29, 611-617.	0.9	29
45	Latest developments in imaging of bladder cancer. Expert Review of Anticancer Therapy, 2010, 10, 881-894.	1.1	2
46	Genetic variation in PSCA and bladder cancer susceptibility in a Chinese population. Carcinogenesis, 2010, 31, 621-624.	1.3	54
47	Recent Advances in Molecular Toxicology of Cadmium and Nickel. Advances in Molecular Toxicology, 2010, 4, 85-126.	0.4	14
48	Variation of Keratin 7 Expression and Other Phenotypic Characteristics of Independent Isolates of Cadmium Transformed Human Urothelial Cells (UROtsa). Chemical Research in Toxicology, 2010, 23, 348-356.	1.7	15
49	Methods for the discovery of low-abundance biomarkers for urinary bladder cancer in biological fluids. Bioanalysis, 2010, 2, 295-309.	0.6	18
50	Estrogen exposure and bladder cancer risk in Egyptian women. Maturitas, 2010, 67, 353-357.	1.0	37
51	Dysfunction of natural killer cells in patients with transitional cell carcinoma. Cancer Letters, 2010, 291, 39-45.	3.2	6
52	Milk and Dairy Consumption and Risk of Bladder Cancer: A Meta-analysis. Urology, 2011, 78, 1298-1305.	0.5	58
53	The role of TP53 PRO47SER and ARG72PRO single nucleotide polymorphisms in the susceptibility to bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 291-294.	0.8	16
54	>Monetary Valuation with Impact Pathway Analysis: Benefits of Reducing Nitrate Leaching in European Catchments. International Review of Environmental and Resource Economics, 2011, 5, 199-244.	1.5	4
55	Uropathogenic bacteria leave a mark. Laboratory Investigation, 2011, 91, 816-818.	1.7	12
56	Intervention of nicotine on MNU-induced bladder cancer in rats. Journal of Huazhong University of Science and Technology [Medical Sciences], 2011, 31, 103-106.	1.0	4
57	Repeated White Light Transurethral Resection of the Bladder in Nonmuscle-Invasive Urothelial Bladder Cancers: Systematic Review and Meta-Analysis. Journal of Endourology, 2011, 25, 1703-1712.	1.1	39

#	ARTICLE Lower Risk in Parous Women Suggests That Hormonal Factors Are Important in Bladder Cancer	IF	CITATIONS
58 59	Etiology. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1156-1170. Transcriptional Profile of Diuron-Induced Toxicity on the Urinary Bladder of Male Wistar Rats to	1.1	44 27
60	Inform Mode of Action. Toxicological Sciences, 2011, 122, 330-338. <i>In vivo</i> Evaluation of Mucoadhesive Nanoparticulate Docetaxel for Intravesical Treatment of Non–Muscle-Invasive Bladder Cancer. Clinical Cancer Research, 2011, 17, 2788-2798.	3.2	52
61	Milk Consumption and Bladder Cancer Risk: A Meta-Analysis of Published Epidemiological Studies. Nutrition and Cancer, 2011, 63, 1263-1271.	0.9	46
62	Chromosome 4p16.3 variant modify bladder cancer risk in a Chinese population. Carcinogenesis, 2011, 32, 872-875.	1.3	23
63	Urinary Bladder Cancer: Role of MR Imaging. Radiographics, 2012, 32, 371-387.	1.4	148
64	Bladder Cancer Survival in a Former Industrial Area in Saxony-Anhalt, Germany. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2012, 75, 1216-1225.	1.1	12
65	Recurrence and Progression in Non-Muscle-Invasive Bladder Cancer Using EORTC Risk Tables. Urologia Internationalis, 2012, 89, 61-66.	0.6	21
66	Urinary Bladder Cancer Risk Factors in Egypt: A Multicenter Case–Control Study. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 537-546.	1.1	61
67	Transitional Cell Carcinoma of the Bladder in Young Adults: Presentation, Natural History, and Outcome of 158 Cases. UroToday International Journal, 2012, 05, .	0.1	1
68	Lack of Association between hOGG1 Ser326Cys Polymorphism and the Risk of Bladder Cancer: A Meta-Analysis. Urologia Internationalis, 2012, 88, 88-94.	0.6	8
69	Bladder Cancer: A Simple Model Becomes Complex. Current Genomics, 2012, 13, 395-415.	0.7	29
70	Bladder Cancer and Stem Cells. Current Signal Transduction Therapy, 2012, 7, 209-219.	0.3	0
71	miR-96 regulates FOXO1-mediated cell apoptosis in bladder cancer. Oncology Letters, 2012, 4, 561-565.	0.8	65
72	Emerging Roles of Cadmium and Heme Oxygenase in Type-2 Diabetes and Cancer Susceptibility. Tohoku Journal of Experimental Medicine, 2012, 228, 267-288.	0.5	50
73	Pretreatment Parameters Obtained from Peripheral Blood Sample Predicts Invasiveness of Bladder Carcinoma. Urologia Internationalis, 2012, 89, 468-472.	0.6	39
74	Exposure of primary porcine urothelial cells to benzo(a)pyrene: in vitro uptake, intracellular concentration, and biological response. Archives of Toxicology, 2012, 86, 1861-1871.	1.9	17
75	Accurate risk assessment of patients with asymptomatic hematuria for the presence of bladder cancer. World Journal of Urology, 2012, 30, 847-852.	1.2	23

#	Article	IF	CITATIONS
76	Clinical characteristics of bladder urothelial tumors in male patients—the influences of benign prostatic hyperplasia/benign prostatic enlargement. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 646-651.	0.8	0
77	Associations differ by sex for catechol-O-methyltransferase genotypes and bladder cancer risk in South Egypt. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 841-847.	0.8	12
79	Genetic Variants in miRNAs Predict Bladder Cancer Risk and Recurrence. Cancer Research, 2012, 72, 6173-6182.	0.4	86
80	Comparison of DNA damage in human-derived hepatoma line (HepG2) exposed to the fifteen drinking water disinfection byproducts using the single cell gel electrophoresis assay. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2012, 741, 89-94.	0.9	73
81	Animal Models for Photodiagnosis and Photodynamic Therapy. Israel Journal of Chemistry, 2012, 52, 706-714.	1.0	2
82	MR Imaging of Urinary Bladder Carcinoma and Beyond. Radiologic Clinics of North America, 2012, 50, 1085-1110.	0.9	14
83	Measures of impact: Diabetes and urothelial cancer. Cancer Epidemiology, 2012, 36, 579-580.	0.8	0
84	Tissue engineering for the oncologic urinary bladder. Nature Reviews Urology, 2012, 9, 561-572.	1.9	44
85	Meta-analysis demonstrates lack of association of the hOGG1 Ser326Cys polymorphism with bladder cancer risk. Genetics and Molecular Research, 2012, 11, 3490-3496.	0.3	13
86	Population densities in relation to bladder cancer mortality rates in America from 1950 to 1994. International Urology and Nephrology, 2012, 44, 443-449.	0.6	12
87	Meat intake and risk of bladder cancer: a meta-analysis. Medical Oncology, 2012, 29, 848-855.	1.2	33
88	<scp><i>hOGG1</i> S</scp> er326 <scp>C</scp> ys polymorphism is associated with risk of bladder cancer in a <scp>C</scp> hinese population: A caseâ€control study. Cancer Science, 2012, 103, 1215-1220.	1.7	31
89	Systematic evaluation of bladder cancer riskâ€associated singleâ€nucleotide polymorphisms in a chinese population. Molecular Carcinogenesis, 2013, 52, 916-921.	1.3	43
90	XRCC1 polymorphisms increase bladder cancer risk in Asians: a meta-analysis. Tumor Biology, 2013, 34, 2659-2664.	0.8	4
91	Constitutional and occupational risk factors associated with bladder cancer. Actas Urológicas Españolas (English Edition), 2013, 37, 513-522.	0.2	10
92	Computed tomography-virtual cystoscopy in the evaluation of a bladder mass: Could it replace standard conventional cystoscopy?. Arab Journal of Urology Arab Association of Urology, 2013, 11, 369-374.	0.7	4
93	The association of cruciferous vegetables intake and risk of bladder cancer: a meta-analysis. World Journal of Urology, 2013, 31, 127-133.	1.2	58
94	Factores de riesgo constitucionales y ocupacionales asociados al cáncer vesical. Actas Urológicas Españolas, 2013, 37, 513-522.	0.3	20

#	Article	IF	CITATIONS
95	Brain-derived neurotrophic factor plus vascular endothelial growth factor additively promotes early growth of the transitional cell carcinoma cell line BFTC905 in vitro and in vivo. Tzu Chi Medical Journal, 2013, 25, 155-160.	0.4	2
96	Quantitative assessment of the associations between XRCC1 polymorphisms and bladder cancer risk. World Journal of Surgical Oncology, 2013, 11, 58.	0.8	15
97	Diabetes Mellitus and Risk of Bladder Cancer: A Meta-Analysis of Cohort Studies. PLoS ONE, 2013, 8, e58079.	1.1	48
98	Detection of herbicides in the urine of pet dogs following home lawn chemical application. Science of the Total Environment, 2013, 456-457, 34-41.	3.9	28
99	Association of p53 Arg72Pro polymorphism with bladder cancer: A meta-analysis. Gene, 2013, 512, 408-413.	1.0	17
100	Novel Role of MDA-9/Syntenin in Regulating Urothelial Cell Proliferation by Modulating EGFR Signaling. Clinical Cancer Research, 2013, 19, 4621-4633.	3.2	54
101	Urinary Bladder Cancer Susceptibility Markers. What Do We Know about Functional Mechanisms?. International Journal of Molecular Sciences, 2013, 14, 12346-12366.	1.8	30
102	Metastatic Bladder Cancer Presenting with Persistent Hematuria in Young Man with Cystic Fibrosis. Case Reports in Pulmonology, 2013, 2013, 1-4.	0.2	0
103	Application of Multi-SNP Approaches Bayesian LASSO and AUC-RF to Detect Main Effects of Inflammatory-Gene Variants Associated with Bladder Cancer Risk. PLoS ONE, 2013, 8, e83745.	1.1	21
105	Genetic Variations rs11892031 and rs401681 Are Associated with Bladder Cancer Risk in a Chinese Population. International Journal of Molecular Sciences, 2014, 15, 19330-19341.	1.8	16
106	Body mass and smoking are modifiable risk factors for recurrent bladder cancer. Cancer, 2014, 120, 408-414.	2.0	78
107	Urinary Bladder Cancer in Dogs, a Naturally Occurring Model for Cancer Biology and Drug Development. ILAR Journal, 2014, 55, 100-118.	1.8	202
108	Low Frequency of HNPCC-Associated Microsatellite Instability and Aberrant MMR Protein Expression in Early-Onset Bladder Cancer. American Journal of Clinical Pathology, 2014, 142, 634-639.	0.4	17
109	MicroRNA-34a functions as an anti-metastatic microRNA and suppresses angiogenesis in bladder cancer by directly targeting CD44. Journal of Experimental and Clinical Cancer Research, 2014, 33, 779.	3.5	89
110	Predicting Recurrence and Progression of Non-Muscle-Invasive Bladder Cancer in Korean Patients: A Comparison of the EORTC and CUETO Models. Korean Journal of Urology, 2014, 55, 643.	1.2	18
111	Agricultural Workers and Urinary Bladder Cancer Risk in Egypt. Archives of Environmental and Occupational Health, 2014, 69, 3-10.	0.7	17
112	Urothelial cancer of bladder in young versus older adults: Clinical and pathological characteristics and outcomes. Kaohsiung Journal of Medical Sciences, 2014, 30, 466-470.	0.8	17
113	MiR-320a down-regulation mediates bladder carcinoma invasion by targeting ITGB3. Molecular Biology Reports, 2014, 41, 2521-2527.	1.0	52

#	Article	IF	CITATIONS
114	Association between CCND1 and XPC polymorphisms and bladder cancer risk: a meta-analysis based on 15 case–control studies. Tumor Biology, 2014, 35, 3155-3165.	0.8	16
115	Oncologic outcomes between open and robotic-assisted radical cystectomy: a propensity score matched analysis. World Journal of Urology, 2014, 32, 1441-1446.	1.2	12
116	Cumulative effect of genomeâ€wide association studyâ€identified genetic variants for bladder cancer. International Journal of Cancer, 2014, 135, 2653-2660.	2.3	31
117	Whole Genome Prediction of Bladder Cancer Risk With the Bayesian LASSO. Genetic Epidemiology, 2014, 38, 467-476.	0.6	11
118	Next generation modeling in GWAS: comparing different genetic architectures. Human Genetics, 2014, 133, 1235-1253.	1.8	17
119	LINE-1 methylation in leukocyte DNA, interaction with phosphatidylethanolamine N-methyltransferase variants and bladder cancer risk. British Journal of Cancer, 2014, 110, 2123-2130.	2.9	17
120	Effects of TSP-1 -696 C/T polymorphism on bladder cancer susceptibility and clinicopathologic features. Cancer Genetics, 2014, 207, 247-252.	0.2	5
121	Citrus fruit intake and bladder cancer risk: a meta-analysis of observational studies. International Journal of Food Sciences and Nutrition, 2014, 65, 893-898.	1.3	21
122	Therapeutic potential of sepantronium bromide YM155 in gemcitabine-resistant human urothelial carcinoma cells. Oncology Reports, 2014, 31, 771-780.	1.2	11
123	Metabolic syndrome and the risk of urothelial carcinoma of the bladder: a case-control study. BMC Cancer, 2015, 15, 720.	1.1	42
124	P70S6K and Elf4E Dual Inhibition Is Essential to Control Bladder Tumor Growth and Progression in Orthotopic Mouse Non-muscle Invasive Bladder Tumor Model. Journal of Korean Medical Science, 2015, 30, 308.	1.1	6
125	miR-34a Inhibits Proliferation and Invasion of Bladder Cancer Cells by Targeting Orphan Nuclear Receptor HNF4G. Disease Markers, 2015, 2015, 1-8.	0.6	35
126	"Lassie,―"Toto,―and Fellow Pet Dogs: Poised to Lead the Way for Advances in Cancer Prevention. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e667-e672.	1.8	12
127	Exposure to polycyclic aromatic hydrocarbons (PAHs) and bladder cancer: evaluation from a gene-environment perspective in a hospital-based case-control study in the Canary Islands (Spain). International Journal of Occupational and Environmental Health, 2015, 21, 23-30.	1.2	51
128	Therapeutic potential of thalidomide for gemcitabine-resistant bladder cancer. International Journal of Oncology, 2015, 47, 1711-1724.	1.4	12
129	Expression of tumor suppressive micro <scp>RNA</scp> â€34a is associated with a reduced risk of bladder cancer recurrence. International Journal of Cancer, 2015, 137, 1158-1166.	2.3	36
130	Nitrate in drinking water and bladder cancer risk in Spain. Environmental Research, 2015, 137, 299-307.	3.7	81
131	Epidemiology of Bladder Cancer. Hematology/Oncology Clinics of North America, 2015, 29, 177-189.	0.9	138

#	Article	IF	Citations
132	Transition and Lifelong Care in Congenital Urology. Current Clinical Urology, 2015, , .	0.0	2
133	The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies. BMC Genomics, 2015, 16, 403.	1.2	86
134	The association between metabolic syndrome and the risk of urothelial carcinoma of the bladder: a case-control study in China. World Journal of Surgical Oncology, 2015, 13, 236.	0.8	14
135	Dermatological exposure to coal tar and bladder cancer risk: A case-control study. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 20.e19-20.e22.	0.8	16
136	CYP1A2-163C/A (rs762551) polymorphism and bladder cancer risk: a case-control study. Genetics and Molecular Research, 2016, 15, .	0.3	2
137	Comparison between standard and reduced volume radiotherapy in bladder preservation trimodality protocol for muscle-invasive bladder cancer patients. Ecancermedicalscience, 2016, 10, 682.	0.6	8
138	Parity, Age at First Birth, and Risk of Death from Bladder Cancer: A Population-Based Cohort Study in Taiwan. International Journal of Environmental Research and Public Health, 2016, 13, 1197.	1.2	4
139	Significant Association of Catechol-O-Methyltransferase Val158Met Polymorphism with Bladder Cancer Instead of Prostate and Kidney Cancer. International Journal of Biological Markers, 2016, 31, 110-117.	0.7	6
140	Correlation between XRCC1 Arg399Gln genetic polymorphisms and susceptibility to bladder cancer: a meta-analysis. OncoTargets and Therapy, 2016, 9, 579.	1.0	5
141	Human Neural Stem Cells Overexpressing a Carboxylesterase Inhibit Bladder Tumor Growth. Molecular Cancer Therapeutics, 2016, 15, 1201-1207.	1.9	2
142	Knockout of phospholipase Cε attenuates N-butyl-N-(4-hydroxybutyl) nitrosamine-induced bladder tumorigenesis. Molecular Medicine Reports, 2016, 13, 2039-2045.	1.1	9
143	Trends in the risk of second primary cancer among bladder cancer survivors: a populationâ€based cohort of 10 047 patients. BJU International, 2016, 118, 53-59.	1.3	12
145	Small-area spatio-temporal analyses of bladder and kidney cancer risk in Nova Scotia, Canada. BMC Public Health, 2016, 16, 175.	1.2	6
146	Sonic hedgehog (Shh) signaling promotes tumorigenicity and stemness via activation of epithelial-to-mesenchymal transition (EMT) in bladder cancer. Molecular Carcinogenesis, 2016, 55, 537-551.	1.3	100
147	Neglected Tropical Diseases - Sub-Saharan Africa. Neglected Tropical Diseases, 2016, , .	0.4	16
148	Long noncoding RNA HOTAIR is a prognostic biomarker and inhibits chemosensitivity to doxorubicin in bladder transitional cell carcinoma. Cancer Chemotherapy and Pharmacology, 2016, 77, 507-513.	1.1	59
149	Organochlorine Pesticides Exposure and Bladder Cancer: Evaluation from a Gene-Environment Perspective in a Hospital-Based Case-Control Study in the Canary Islands (Spain). Journal of Agromedicine, 2016, 21, 34-42.	0.9	14
152	Long noncoding RNA GAS5 inhibits malignant proliferation and chemotherapy resistance to doxorubicin in bladder transitional cell carcinoma. Cancer Chemotherapy and Pharmacology, 2017, 79, 49-55.	1.1	87

#	Article	IF	Citations
153	The Role of Cytologic Analysis in Follow-Up of Non-Muscle Invaisve Urothelial Cell Carcinoma in Relation to Cystoscopic Biopsy. Journal of Molecular Biomarkers & Diagnosis, 2017, 08, .	0.4	0
154	Differential expression of cytokeratin 14 and 18 in bladder cancer tumorigenesis. Experimental Biology and Medicine, 2018, 243, 344-349.	1.1	4
155	Red and processed meat consumption and risk of bladder cancer: a dose–response meta-analysis of epidemiological studies. European Journal of Nutrition, 2018, 57, 689-701.	1.8	51
156	Predicting the cancer burden in Catalonia between 2015 and 2025: the challenge of cancer management in the elderly. Clinical and Translational Oncology, 2018, 20, 647-657.	1.2	12
157	Factors Affecting Survival in Egyptian Patients Suffering from Urinary Bladder Cancer: A Multicenter Retrospective Study. Journal of Cancer Science & Therapy, 2018, 10, .	1.7	1
158	The prognostic impact of incidental prostate cancer following radical cystoprostatectomy: a nationwide analysis. Scandinavian Journal of Urology, 2018, 52, 358-363.	0.6	8
159	Targeted and Untargeted Detection of DNA Adducts of Aromatic Amine Carcinogens in Human Bladder by Ultra-Performance Liquid Chromatography-High-Resolution Mass Spectrometry. Chemical Research in Toxicology, 2018, 31, 1382-1397.	1.7	39
160	Genetic Testing, Genetic Variation, and Genetic Susceptibility. , 2018, , 629-649.		0
161	Increased CD4+ T cell lineage commitment determined by CpG methylation correlates with better prognosis in urinary bladder cancer patients. Clinical Epigenetics, 2018, 10, 102.	1.8	24
162	Bladder Cancer in Lebanon. Cancer Control, 2018, 25, 107327481878935.	0.7	10
163	Pioglitazone use in patients with diabetes and risk of bladder cancer: a systematic review and meta-analysis. Cancer Management and Research, 2018, Volume 10, 1627-1638.	0.9	24
164	Enhancer RNA - P2RY2e induced by estrogen promotes malignant behaviors of bladder cancer. International Journal of Biological Sciences, 2018, 14, 1268-1276.	2.6	23
165	High expression of spindle and kinetochore- associated protein 1 predicts early recurrence and progression of non-muscle invasive bladder cancer. Cancer Biomarkers, 2018, 22, 543-549.	0.8	10
166	In silico design and in vitro characterization of a recombinant antigen for specific recognition of NMP22. International Journal of Biological Macromolecules, 2019, 140, 69-77.	3.6	2
167	lncRNA MIR503HG functioned as a tumor suppressor and inhibited cell proliferation, metastasis and epithelialâ€mesenchymal transition in bladder cancer. Journal of Cellular Biochemistry, 2019, 120, 10821-10829.	1.2	32
168	MicroRNA Dysregulation and Non-Muscle–Invasive Bladder Cancer Prognosis. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 782-788.	1.1	19
169	A review of incidence and mortality of colorectal, lung, liver, thyroid, and bladder cancers in Iran and compared to other countries. Wspolczesna Onkologia, 2019, 23, 7-15.	0.7	26
170	Intake of milk and other dairy products and the risk of bladder cancer: a pooled analysis of 13 cohort studies. European Journal of Clinical Nutrition, 2020, 74, 28-35.	1.3	16

#	Article	IF	CITATIONS
171	Peptidyl Arginine Deiminase, Type II (PADI2) Is Involved in Urothelial Bladder Cancer. Pathology and Oncology Research, 2020, 26, 1279-1285.	0.9	4
172	Apaziquone for Nonmuscle Invasive Bladder Cancer. Urologic Clinics of North America, 2020, 47, 73-82.	0.8	5
173	Gene-environment interaction with smoking for increased non- muscle-invasive bladder cancer tumor size. Translational Andrology and Urology, 2020, 9, 1329-1337.	0.6	6
174	Interactions between Cisplatin and Quercetin at Physiological and Hyperthermic Conditions on Cancer Cells In Vitro and In Vivo. Molecules, 2020, 25, 3271.	1.7	15
175	Identification of Let-7f-5p as a novel biomarker of recurrence in non-muscle invasive bladder cancer. Cancer Biomarkers, 2020, 29, 101-110.	0.8	12
176	Genetic and molecular biology of bladder cancer among Iranian patients. Molecular Genetics & Genomic Medicine, 2020, 8, e1233.	0.6	11
177	Overview of VI-RADS in Bladder Cancer. American Journal of Roentgenology, 2020, 214, 1259-1268.	1.0	47
178	Correlation between immunohistochemical expression of Ki-67and P63 and aggressiveness of urinary bladder urothelial carcinoma. Journal of Immunoassay and Immunochemistry, 2021, 42, 188-201.	0.5	2
179	Dietary N-nitroso compounds intake and bladder cancer risk: A systematic review and meta-analysis. Nitric Oxide - Biology and Chemistry, 2021, 115, 1-7.	1.2	6
180	Bladder Carcinogenesis and Molecular Pathways. , 2011, , 23-41.		1
181	Identification of γ-Synuclein as a Stage-Specific Marker in Bladder Cancer by Immunohistochemistry. Medical Science Monitor, 2014, 20, 2550-2555.	0.5	12
182	Up-Regulation of miR-9 Target CBX7 to Regulate Invasion Ability of Bladder Transitional Cell Carcinoma. Medical Science Monitor, 2015, 21, 225-230.	0.5	33
183	XRCC1 Arg194Trp and Arg280His Polymorphisms Increase Bladder Cancer Risk in Asian Population: Evidence from a Meta-Analysis. PLoS ONE, 2013, 8, e64001.	1.1	14
184	Functional Promoter -94 ins/del ATTG Polymorphism in NFKB1 Gene Is Associated with Bladder Cancer Risk in a Chinese Population. PLoS ONE, 2013, 8, e71604.	1.1	30
185	Prognostic Role of Epithelial-Mesenchymal Transition Markers "E-Cadherin, β-Catenin, ZEB1, ZEB2 and p63―in Bladder Carcinoma. World Journal of Oncology, 2019, 10, 199-217.	0.6	15
186	Mitigation of aflatoxin B ₁ - and sodium arsenite-induced cytotoxicities in HUC-PC urinary bladder cells by curcumin and <i>Khaya senegalensis</i> . Journal of Basic and Clinical Physiology and Pharmacology, 2020, 31, .	0.7	4
187	Environment and bladder cancer: molecular analysis by interaction networks. Oncotarget, 2017, 8, 65240-65252.	0.8	39
188	Blue-light cystoscopy and narrow-band imaging in bladder cancer management. Formosan Journal of Surgery, 2019, 52, 155.	0.1	3

#	Article	IF	CITATIONS
189	Epidemiologic and Socioeconomic Status of Bladder Cancer in Mazandaran province, Northern Iran. Asian Pacific Journal of Cancer Prevention, 2012, 13, 5053-5056.	0.5	23
190	The NQO1 rs1800566 Polymorphism and Risk of Bladder Cancer: Evidence from 6,169 Subjects. Asian Pacific Journal of Cancer Prevention, 2012, 13, 6343-6348.	0.5	11
191	Obesity and Risk of Bladder Cancer: A Meta-analysis of Cohort Studies. Asian Pacific Journal of Cancer Prevention, 2013, 14, 3117-3121.	0.5	78
192	The MDM2 SNP309T>G Polymorphism Increases Bladder Cancer Risk among Caucasians: a Meta-analysis. Asian Pacific Journal of Cancer Prevention, 2014, 15, 5277-5281.	0.5	4
193	Association between the Metabolic Syndrome and High Tumor Grade and Stage of Primary Urothelial Cell Carcinoma of the Bladder. Asian Pacific Journal of Cancer Prevention, 2014, 15, 1447-1451.	0.5	14
194	Incidence and Mortality of Bladder Cancer and their Relationship with Development in Asia. Asian Pacific Journal of Cancer Prevention, 2015, 16, 7365-7374.	0.5	48
195	Clinical Approach. , 2009, , 127-134.		0
197	Histopathology and Molecular Pathology of Bladder Cancer. , 2011, , 43-61.		0
198	Harntrakt. , 2011, , 229-255.		0
199	Role of Diagnostic Testing in Schistosomiasis Control Programs in Rural Ghana. Journal of Bacteriology & Parasitology, 2011, 02, .	0.2	1
200	Augmentation Cystoplasty: Risks for Malignancy and Suggestions for Follow-Up Evaluations. Current Clinical Urology, 2015, , 123-130.	0.0	0
202	Utility of SOX2 and Livin Co-Expression in the Prognosis of Bladder Cancer With Bilharzial and Non-Bilharzial Bladder Status. World Journal of Oncology, 2015, 6, 446-455.	0.6	6
203	AB111. Genetic variations rs11892031 and rs401681 are associated with bladder cancer risk in a Chinese population. Translational Andrology and Urology, 2016, 5, AB111-AB111.	0.6	0
204	Preparation and Characterization of Monoclonal Antibody Against Truncated Recombinant Nuclear Matrix Protein (NMP22). Biotechnology and Health Sciences, 2016, In Press, .	0.3	0
205	Association of TP53 Arg72Pro polymorphism (rs1042522) with bladder cancer risk in the Ukrainian population. Faktori Eksperimental Noi Evolucii Organizmiv, 0, 23, 214-218.	0.0	0
206	Quantitative and qualitative characteristics of polypeptide pool in patients with bladder cancer. ScienceRise Biological Science, 2018, .	0.1	0
207	The bladder cancer: the risk factors and prognostic markers. Klinichna Khirurhiia, 2019, 86, 78-84.	0.0	1
208	Proteolytic parameter changes in the plasma of patients with bladder cancer – depending on tumor stage. Current Issues in Pharmacy and Medical Sciences, 2020, 33, 67-71.	0.1	1

#	Article	IF	CITATIONS
209	Association between Metabolic Syndrome and tumor histologic grade and pathologic stage of bladder cancer. Archive of Urological Research, 2020, , 085-089.	0.0	0
210	The Attitudes and Awareness of Urinary Bladder Cancer Patients about the Relationship Between Their Tumoral Diseases and Tobacco Exposure. Journal of Contemporary Medicine, 2020, 10, 359-364.	0.1	1
211	Risk factors for bladder cancer: challenges of conducting a literature search using PubMed. Perspectives in Health Information Management / AHIMA, American Health Information Management Association, 2011, 8, 1e.	0.0	2
212	Red and processed meat intake and risk of bladder cancer: a meta-analysis. International Journal of Clinical and Experimental Medicine, 2014, 7, 2100-10.	1.3	22
213	The association between rs9642880 gene polymorphism and bladder cancer risk: a meta-analysis. International Journal of Clinical and Experimental Medicine, 2015, 8, 20236-44.	1.3	3
214	LncRNA MALAT1 promotes tumor growth and metastasis by targeting miR-124/foxq1 in bladder transitional cell carcinoma (BTCC). American Journal of Cancer Research, 2018, 8, 748-760.	1.4	30
215	Urinary Bladder Tumors Clinical and Statistical Retrospective Study. Current Health Sciences Journal, 2018, 44, 64-70.	0.2	1
216	True collision renal tumour of oncocytoma and papillary Renal cell carcinoma: Case Report and Review of the Literature. Archive of Urological Research, 2020, , 080-084.	0.0	0
217	Age of menarche and primary bladder cancer risk: A meta-analysis and systematic review. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 346.e17-346.e26.	0.8	3
218	Approccio anatomo-clinico. , 0, , 127-134.		0
220	Causal relationship between smoking status, smoking frequency and bladder cancer: a Mendelian randomization study. Genes and Genomics, 2023, 45, 203-213.	0.5	7
221	Review on Bladder Cancer Diagnosis. , 0, , .		0